NCT00404729View on ClinicalTrials.gov

Neural Conduction Along the Visual Pathways After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

February 28, 2006

Study Completion Date

July 30, 2006

Conditions

GlaucomaOptic Neuropathy, IschemicVisual Pathway DisorderOptic NerveNeural Conduction

Interventions

DRUG

Citicoline

Ten OAG patients will be untreated (NT-AOG, 10 eyes), while 20 OAG patients (T-AOG, 20 eyes) and 15 NION patients (T-NION, 14 eyes) were treated with Citicoline (oral treatment:1600 mg/die per 60 days)

Trial Locations (2)

00199

Fondazione G.B. Bietti- IRCCS, Rome

Fondazione G.B. Bietti-IRCCS, Rome

All Listed Sponsors

lead

Fondazione G.B. Bietti, IRCCS

OTHER

NCT00404729 - Neural Conduction Along the Visual Pathways After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases | Biotech Hunter | Biotech Hunter